Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody
Identifieur interne : 000A98 ( 2020/Analysis ); précédent : 000A97; suivant : 000A99Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody
Auteurs : Paul K. S. Chan [République populaire de Chine, Hong Kong] ; W. K. To [République populaire de Chine] ; Esther Y. M. Liu [République populaire de Chine] ; T. K. Ng [République populaire de Chine] ; John S. Tam [République populaire de Chine] ; Joseph J. Y. Sung [République populaire de Chine] ; Jean-Michel Lacroix [Canada] ; Michel Houde [Canada]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 2004-12.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Coronavirus (génétique), Coronavirus (isolement et purification), Enfant, Enfant d'âge préscolaire, Femelle, Humains, Immunoglobuline G (analyse), Immunoglobuline G (immunologie), Mâle, Nourrisson, Nucléocapside (analyse), Sensibilité et spécificité, Sujet âgé, Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Syndrome respiratoire aigu sévère (épidémiologie), Test ELISA, Tests sérologiques (), Virus du SRAS (immunologie), Études d'évaluation comme sujet.
- MESH :
- analyse : Immunoglobuline G, Nucléocapside.
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Coronavirus.
- immunologie : Immunoglobuline G, Syndrome respiratoire aigu sévère, Virus du SRAS.
- isolement et purification : Coronavirus.
- virologie : Syndrome respiratoire aigu sévère.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- MESH :
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antibody, Child, Child, Preschool, Coronavirus (genetics), Coronavirus (isolation & purification), Enzyme immunoassay, Enzyme-Linked Immunosorbent Assay, Evaluation Studies as Topic, Female, Humans, IgG, Immunoglobulin G (analysis), Immunoglobulin G (immunology), Infant, Male, Middle Aged, Nucleocapsid (analysis), Peptides, SARS Virus (immunology), Sensitivity and Specificity, Serologic Tests (methods), Serology, Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus.
- MESH :
- chemical , analysis : Immunoglobulin G.
- analysis : Nucleocapsid.
- diagnosis : Severe Acute Respiratory Syndrome.
- epidemiology : Severe Acute Respiratory Syndrome.
- genetics : Coronavirus.
- chemical , immunology : Immunoglobulin G, SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : Coronavirus.
- methods : Serologic Tests.
- virology : Severe Acute Respiratory Syndrome.
- Teeft :
- Absorbance indices, Adolescent, Adult, Aged, Amino acids, Assay, Chan, Child, Child, Preschool, Chinese university, Coronavirus, Disease control, Enzyme immunoassay, Enzyme-Linked Immunosorbent Assay, Evaluation Studies as Topic, Female, Healthy controls, High degree, Hong kong, Humans, Index values, Indirect assay, Infant, Infectious diseases, Large number, Male, Microplate enzyme immunoassay, Middle Aged, Novel coronavirus, Peptide, Respiratory syndrome, Sars, Sars group, Sars patients, Sars study group, Sensitivity and Specificity, Serum specimens, Spike protein, Spike proteins, Syndrome, Synthetic peptides, Various control groups, Wales hospital, World health organization.
Abstract
High throughput assays for anti‐SARS‐CoV IgG antibody detection are need for large‐scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT‐SARS™, was evaluated for the detection of anti‐SARS‐CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high‐throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required. J. Med. Virol. 74:517–520, 2004. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.20207
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000990
- to stream Istex, to step Curation: 000990
- to stream Istex, to step Checkpoint: 001F67
- to stream PubMed, to step Corpus: 002B14
- to stream PubMed, to step Curation: 002B14
- to stream PubMed, to step Checkpoint: 002D18
- to stream Ncbi, to step Merge: 000B19
- to stream Ncbi, to step Curation: 000B19
- to stream Ncbi, to step Checkpoint: 000B19
- to stream Main, to step Merge: 005D34
- to stream PascalFrancis, to step Corpus: 000616
- to stream PascalFrancis, to step Curation: 000374
- to stream PascalFrancis, to step Checkpoint: 000853
- to stream Main, to step Merge: 006004
- to stream Main, to step Curation: 005888
- to stream Main, to step Exploration: 005888
- to stream 2020, to step Extraction: 000A98
Links to Exploration step
ISTEX:0739D6E4A307DF53586757BAC1A3D2894AF8E248Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody</title><author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name></author><author><name sortKey="To, W K" sort="To, W K" uniqKey="To W" first="W. K." last="To">W. K. To</name></author><author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name></author><author><name sortKey="Ng, T K" sort="Ng, T K" uniqKey="Ng T" first="T. K." last="Ng">T. K. Ng</name></author><author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name></author><author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J. Y." last="Sung">Joseph J. Y. Sung</name></author><author><name sortKey="Lacroix, Jean Ichel" sort="Lacroix, Jean Ichel" uniqKey="Lacroix J" first="Jean-Michel" last="Lacroix">Jean-Michel Lacroix</name></author><author><name sortKey="Houde, Michel" sort="Houde, Michel" uniqKey="Houde M" first="Michel" last="Houde">Michel Houde</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0739D6E4A307DF53586757BAC1A3D2894AF8E248</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/jmv.20207</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-2B8N0VCT-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000990</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000990</idno><idno type="wicri:Area/Istex/Curation">000990</idno><idno type="wicri:Area/Istex/Checkpoint">001F67</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F67</idno><idno type="wicri:doubleKey">0146-6615:2004:Chan P:evaluation:of:a</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15484283</idno><idno type="wicri:Area/PubMed/Corpus">002B14</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B14</idno><idno type="wicri:Area/PubMed/Curation">002B14</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B14</idno><idno type="wicri:Area/PubMed/Checkpoint">002D18</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002D18</idno><idno type="wicri:Area/Ncbi/Merge">000B19</idno><idno type="wicri:Area/Ncbi/Curation">000B19</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B19</idno><idno type="wicri:doubleKey">0146-6615:2004:Chan P:evaluation:of:a</idno><idno type="wicri:Area/Main/Merge">005D34</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0395225</idno><idno type="wicri:Area/PascalFrancis/Corpus">000616</idno><idno type="wicri:Area/PascalFrancis/Curation">000374</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000853</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000853</idno><idno type="wicri:doubleKey">0146-6615:2004:Chan P:evaluation:of:a</idno><idno type="wicri:Area/Main/Merge">006004</idno><idno type="wicri:Area/Main/Curation">005888</idno><idno type="wicri:Area/Main/Exploration">005888</idno><idno type="wicri:Area/2020/Extraction">000A98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody</title><author><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Hong Kong</country></affiliation><affiliation wicri:level="4"><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Correspondence address: Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="To, W K" sort="To, W K" uniqKey="To W" first="W. K." last="To">W. K. To</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pathology, Princess Margaret Hospital, Kowloon, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Ng, T K" sort="Ng, T K" uniqKey="Ng T" first="T. K." last="Ng">T. K. Ng</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pathology, Princess Margaret Hospital, Kowloon, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J. Y." last="Sung">Joseph J. Y. Sung</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Lacroix, Jean Ichel" sort="Lacroix, Jean Ichel" uniqKey="Lacroix J" first="Jean-Michel" last="Lacroix">Jean-Michel Lacroix</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Adaltis Development, Inc., Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Houde, Michel" sort="Houde, Michel" uniqKey="Houde M" first="Michel" last="Houde">Michel Houde</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Adaltis Development, Inc., Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">74</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="517">517</biblScope><biblScope unit="page" to="520">520</biblScope><biblScope unit="page-count">4</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antibody</term><term>Child</term><term>Child, Preschool</term><term>Coronavirus (genetics)</term><term>Coronavirus (isolation & purification)</term><term>Enzyme immunoassay</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Evaluation Studies as Topic</term><term>Female</term><term>Humans</term><term>IgG</term><term>Immunoglobulin G (analysis)</term><term>Immunoglobulin G (immunology)</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Nucleocapsid (analysis)</term><term>Peptides</term><term>SARS Virus (immunology)</term><term>Sensitivity and Specificity</term><term>Serologic Tests (methods)</term><term>Serology</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Coronavirus (génétique)</term><term>Coronavirus (isolement et purification)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Immunoglobuline G (analyse)</term><term>Immunoglobuline G (immunologie)</term><term>Mâle</term><term>Nourrisson</term><term>Nucléocapside (analyse)</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Test ELISA</term><term>Tests sérologiques ()</term><term>Virus du SRAS (immunologie)</term><term>Études d'évaluation comme sujet</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Immunoglobuline G</term><term>Nucléocapside</term></keywords><keywords scheme="MESH" qualifier="analysis" xml:lang="en"><term>Nucleocapsid</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Immunoglobuline G</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Immunoglobulin G</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Serologic Tests</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticorps</term><term>IgG</term><term>Méthode immunoenzymatique</term><term>Peptide</term><term>Syndrome respiratoire aigu sévère</term><term>Sérologie</term><term>Virus syndrome respiratoire aigu sévère</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Absorbance indices</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Amino acids</term><term>Assay</term><term>Chan</term><term>Child</term><term>Child, Preschool</term><term>Chinese university</term><term>Coronavirus</term><term>Disease control</term><term>Enzyme immunoassay</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Evaluation Studies as Topic</term><term>Female</term><term>Healthy controls</term><term>High degree</term><term>Hong kong</term><term>Humans</term><term>Index values</term><term>Indirect assay</term><term>Infant</term><term>Infectious diseases</term><term>Large number</term><term>Male</term><term>Microplate enzyme immunoassay</term><term>Middle Aged</term><term>Novel coronavirus</term><term>Peptide</term><term>Respiratory syndrome</term><term>Sars</term><term>Sars group</term><term>Sars patients</term><term>Sars study group</term><term>Sensitivity and Specificity</term><term>Serum specimens</term><term>Spike protein</term><term>Spike proteins</term><term>Syndrome</term><term>Synthetic peptides</term><term>Various control groups</term><term>Wales hospital</term><term>World health organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Test ELISA</term><term>Tests sérologiques</term><term>Études d'évaluation comme sujet</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High throughput assays for anti‐SARS‐CoV IgG antibody detection are need for large‐scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT‐SARS™, was evaluated for the detection of anti‐SARS‐CoV IgG antibody. This assay is based on synthetic peptides derived from the nucleocapsid and spike proteins. The results showed that the assay provided a high degree of sensitivity (95.9%) for convalescent serum samples. The level of specificity was close to 90%, and did not show significant variation among different control groups. The high degree of sensitivity together with the high‐throughput nature makes it advantageous as a screening assay for studies where handling of a large number of specimens is required. J. Med. Virol. 74:517–520, 2004. © 2004 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Hong Kong</li><li>République populaire de Chine</li></country><settlement><li>Sha Tin</li></settlement><orgName><li>Université chinoise de Hong Kong</li></orgName></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name></noRegion><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name><name sortKey="Liu, Esther Y M" sort="Liu, Esther Y M" uniqKey="Liu E" first="Esther Y. M." last="Liu">Esther Y. M. Liu</name><name sortKey="Ng, T K" sort="Ng, T K" uniqKey="Ng T" first="T. K." last="Ng">T. K. Ng</name><name sortKey="Sung, Joseph J Y" sort="Sung, Joseph J Y" uniqKey="Sung J" first="Joseph J. Y." last="Sung">Joseph J. Y. Sung</name><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name><name sortKey="Tam, John S" sort="Tam, John S" uniqKey="Tam J" first="John S." last="Tam">John S. Tam</name><name sortKey="To, W K" sort="To, W K" uniqKey="To W" first="W. K." last="To">W. K. To</name></country><country name="Hong Kong"><noRegion><name sortKey="Chan, Paul K S" sort="Chan, Paul K S" uniqKey="Chan P" first="Paul K. S." last="Chan">Paul K. S. Chan</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Lacroix, Jean Ichel" sort="Lacroix, Jean Ichel" uniqKey="Lacroix J" first="Jean-Michel" last="Lacroix">Jean-Michel Lacroix</name></noRegion><name sortKey="Houde, Michel" sort="Houde, Michel" uniqKey="Houde M" first="Michel" last="Houde">Michel Houde</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000A98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= ISTEX:0739D6E4A307DF53586757BAC1A3D2894AF8E248
|texte= Evaluation of a peptide‐based enzyme immunoassay for anti‐SARS coronavirus IgG antibody
}}
| This area was generated with Dilib version V0.6.33. |  |